1-6 of 6
Hans-Juergen Hurtz
Close
Sort by
Journal Articles

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Tony Hennersdorf, Nadja Jaekel, Susann Schulze, MD, Dietrich Kaempfe, MD, Claudia Spohn, MD, Regina Moeller, MD, Maik Schwarz, MD, Hans-Juergen Hurtz, MD, Joern Ruessel, MD, Peter Tornow, Ute Neef, MD, Marion Schmalfeld, MD, Kathleen Jentsch-Ullrich, MD, Thoralf Lange, MD, Christian Junghanss, MD, Brigitte Kragl, MD, Haifa Kathrin Al-Ali, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-139366
Published: 2020
Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Florian Zettl, Friederike Braulke, Marita Ziepert, PhD, Andreas Viardot, MD PhD, Christoph Kahl, MD, Gabriele Prange-Krex, Agnieszka Korfel, Martin H. Dreyling, MD PhD, Thomas Illmer, MD, Josef Birkmann, MD, Ulrich Wedding, Dietmar Reichert, Maike de Wit, MD, Frank Hartmann, MD, Hans-Juergen Hurtz, Norbert Schmitz, MD, Mathias Witzens-Harig, MD, Wolfram Klapper, Andreas Rosenwald, MD, Viola Poeschel, MD, Markus Loeffler, MD, Gerald Wulf, MD, Bettina Altmann, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4073.
https://doi.org/10.1182/blood-2019-122948
Published: 2019
Journal Articles

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Wolfgang Knauf, Andreas Ammon, Jens Uhlig, Marie Merling, Hans-Juergen Hurtz, Corinne Vannier, Holger Schulz, Norbert Marschner, Tamara Riedt, PhD, Karin Potthoff
Journal: Blood
Blood (2018) 132 (Supplement 1): 5662.
https://doi.org/10.1182/blood-2018-99-117996
Published: 2018
Journal Articles

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Wolfram Poenisch, Malvina Bourgeois, Barbara Moll, Simone Heyn, Nadja Jäkel, Robert Rohrberg, Hans Juergen Hurtz, Marion Schmalfeld, Michael Assmann, Thomas Edelmann, Martin Mohren, MD, Franz-Albert Hoffmann, Andreas Schwarzer, MD, Gerald Hensel, Kerstin Loeschcke, Cornelia Becker, MD, Rainer Krahl, MD, Ina Wagner, Haifa K. Al-Ali, MD, Dietger Niederwieser
Journal: Blood
Blood (2012) 120 (21): 1855.
https://doi.org/10.1182/blood.V120.21.1855.1855
Published: 2012
Journal Articles

Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group

Petra Jenke, Barbara Eichhorst, MD, Raymonde Busch, Nadine Anheier, Ulrich Duehrsen, MD, Jan Duerig, Martin H. Dreyling, PhD, Manuela Bergmann, MD, Maria Elisabeth Goebeler, Hans Juergen Hurtz, Martina Beate Stauch, Stephan Stilgenbauer, MD, Hartmut Doehner, Prof. Dr. med., Anna-Maria Fink, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD
Journal: Blood
Blood (2011) 118 (21): 2860.
https://doi.org/10.1182/blood.V118.21.2860.2860
Published: 2011
Journal Articles

Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma.

Wolfram Poenisch, MD, Malvina Bourgeois, Song-Yau Wang, Simone Heyn, Nadja Jaekel, Leanthe Braunert, Robert Rohrberg, MD, Hans Juergen Hurtz, MD, Franz Albert Hoffmann, MD, Andreas Schwarzer, MD, Cornelia Becker, MD, Haifa Al Ali, MD, Dietger W. Niederwieser, MD
Journal: Blood
Blood (2007) 110 (11): 2723.
https://doi.org/10.1182/blood.V110.11.2723.2723
Published: 2007